Andrea MAHR,Toni WEINSCHENK,Oliver SCHOOR,Jens FRITSCHE,Harpreet SINGH,Phillip MÜLLER,Julia LEIBOLD,Valentina GOLDFINGER
申请号：
US16100498
公开号：
US20180344827A1
申请日:
2018.08.10
申请国别(地区):
US
年份:
2018
代理人:
摘要：
A method of treating a patient who has prostate cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has prostate cancer. A method of treating a patient who has prostate cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the prostate cancer.
